# Viela Bio, Inc. (VIE)

Source: https://www.quantisnow.com/company/VIE
Generated: 2026-11-13T17:05:04.967Z

- Ticker: VIE
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Major Pharmaceuticals
- IPO year: 2019

## Latest VIE news and filings

- 2021-03-25 20:01 UTC [SEC Form 15-12B] [SEC Form 15-12B filed by Viela Bio, Inc.](https://www.quantisnow.com/insight/sec-form-15-12b-filed-by-viela-bio-inc-554537)
- 2021-03-17 11:40 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Viela Bio, Inc.](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-viela-bio-inc-520423)
- 2021-03-16 21:13 UTC [SEC Form 4] [SEC Form 4: Yanling Cao disposed to the issuer $441,084,709 worth of Common Stock (8,322,353 units at $53.00)](https://www.quantisnow.com/insight/sec-form-4-yanling-cao-disposed-to-the-issuer-441084709-518584)
- 2021-03-16 12:53 UTC [SEC Form 4] [SEC Form 4 filed by Tyrell Rivers](https://www.quantisnow.com/insight/sec-form-4-filed-by-tyrell-rivers-515360)
- 2021-03-16 12:52 UTC [SEC Form 4] [SEC Form 4 filed by Plc Astrazeneca](https://www.quantisnow.com/insight/sec-form-4-filed-by-plc-astrazeneca-515359)
- 2021-03-15 21:57 UTC [SEC Form 4] [SEC Form 4: Andreas Wicki disposed to the issuer $92,750,000 worth of Common Stock (1,750,000 units at $53.00)](https://www.quantisnow.com/insight/sec-form-4-andreas-wicki-disposed-to-the-issuer-92750000-513002)
- 2021-03-15 20:52 UTC [SEC Form 4] [SEC Form 4: Edward Hu disposed to the issuer $220,542,381 worth of Common Stock (4,161,177 units at $53.00)](https://www.quantisnow.com/insight/sec-form-4-edward-hu-disposed-to-the-issuer-220542381-512505)
- 2021-03-15 13:28 UTC [SEC Form 4] [SEC Form 4 filed by Ltd Meadow Boundless](https://www.quantisnow.com/insight/sec-form-4-filed-by-ltd-meadow-boundless-510585)
- 2021-03-15 13:17 UTC [SEC Form 4] [SEC Form 4: Mitchell Chan disposed to the issuer $1,987,500 worth of Common Stock (37,500 units at $53.00), decreasing direct ownership by 100% to 0 units](https://www.quantisnow.com/insight/sec-form-4-mitchell-chan-disposed-to-the-issuer-1987500-510539)
- 2021-03-15 13:16 UTC [SEC Form 4] [SEC Form 4: Jorn Drappa disposed to the issuer $10,741,033 worth of Common Stock (202,661 units at $53.00), decreasing direct ownership by 100% to 0 units](https://www.quantisnow.com/insight/sec-form-4-jorn-drappa-disposed-to-the-issuer-10741033-510535)
- 2021-03-15 13:16 UTC [SEC Form 4] [SEC Form 4 filed by Paul James Kastenmayer](https://www.quantisnow.com/insight/sec-form-4-filed-by-paul-james-kastenmayer-510533)
- 2021-03-15 13:15 UTC [SEC Form S-8 POS filed by Viela Bio, Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-viela-bio-inc-510530)
- 2021-03-15 13:15 UTC [SEC Form 4] [SEC Form 4 filed by Suzanne Rachelle Jacques](https://www.quantisnow.com/insight/sec-form-4-filed-by-suzanne-rachelle-jacques-510526)
- 2021-03-15 13:15 UTC [SEC Form 4] [SEC Form 4 filed by Chris Nolet](https://www.quantisnow.com/insight/sec-form-4-filed-by-chris-nolet-510525)
- 2021-03-15 13:15 UTC [SEC Form 4] [SEC Form 4: Zhengbin Yao disposed to the issuer $24,921,607 worth of Common Stock (470,219 units at $53.00), decreasing direct ownership by 100% to 0 units](https://www.quantisnow.com/insight/sec-form-4-zhengbin-yao-disposed-to-the-issuer-24921607-510523)
- 2021-03-15 13:15 UTC [SEC Form 4] [SEC Form 4: William Ragatz disposed to the issuer $861,250 worth of Common Stock (16,250 units at $53.00), decreasing direct ownership by 100% to 0 units](https://www.quantisnow.com/insight/sec-form-4-william-ragatz-disposed-to-the-issuer-861250-510522)
- 2021-03-15 13:12 UTC [SEC Form S-8 POS filed by Viela Bio, Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-viela-bio-inc-510504)
- 2021-03-15 13:10 UTC [SEC Form POSASR filed by Viela Bio, Inc.](https://www.quantisnow.com/insight/sec-form-posasr-filed-by-viela-bio-inc-510486)
- 2021-03-15 13:02 UTC [SEC Form 8-K] [SEC Form 8-K filed by Viela Bio, Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-viela-bio-inc-510446)
- 2021-03-15 12:57 UTC [SEC Schedule 14D-9] [SEC Form SC 14D9/A filed by Viela Bio, Inc.](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-by-viela-bio-inc-510273)
- 2021-03-15 12:45 UTC [SEC Form 25-NSE filed by Viela Bio, Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-viela-bio-inc-510212)
- 2021-03-15 12:27 UTC [SEC Schedule TOT] [SEC Form SC TO-T/A filed by Viela Bio, Inc.](https://www.quantisnow.com/insight/sec-form-sc-to-ta-filed-by-viela-bio-inc-510032)
- 2021-03-12 22:16 UTC [SEC Form SC TO-T/A filed](https://www.quantisnow.com/insight/sec-form-sc-to-ta-filed-507557)
- 2021-03-12 22:15 UTC [SEC Form SC 14D9/A filed](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-507550)
- 2021-03-10 14:46 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-494507)
- 2021-03-08 22:13 UTC [SEC Form SC 14D9/A filed](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-485276)
- 2021-03-04 21:06 UTC [SEC Form 8-K filed](https://www.quantisnow.com/insight/sec-form-8-k-filed-474419)
- 2021-03-04 02:54 UTC [SEC Form SC TO-T/A filed](https://www.quantisnow.com/insight/sec-form-sc-to-ta-filed-470890)
- 2021-03-03 17:26 UTC [SEC Form SC 14D9/A filed](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-466479)
- 2021-03-01 21:39 UTC [SEC Form 10-K filed](https://www.quantisnow.com/insight/sec-form-10-k-filed-454202)
- 2021-03-01 21:11 UTC [SEC Form 8-K filed](https://www.quantisnow.com/insight/sec-form-8-k-filed-453554)
- 2021-03-01 21:01 UTC [Public Offering] [Viela Bio Reports Fourth Quarter and Full Year 2020 Operating and Financial Results](https://www.quantisnow.com/insight/viela-bio-reports-fourth-quarter-and-full-year-2020-operating-453277)
- 2021-02-26 11:06 UTC [SEC Form SC TO-T/A filed](https://www.quantisnow.com/insight/sec-form-sc-to-ta-filed-444230)
- 2021-02-25 13:30 UTC [Viela Bio Announces Additional Positive Results with UPLIZNA® (inebilizumab-cdon) in Patients with Neuromyelitis Optica Spectrum Disorder at the ACTRIMS 2021 Forum](https://www.quantisnow.com/insight/viela-bio-announces-additional-positive-results-with-uplizna-inebilizumab-cdon-in-432229)
- 2021-02-24 11:30 UTC [SEC Form SC 14D9/A filed](https://www.quantisnow.com/insight/sec-form-sc-14d9a-filed-426370)
- 2021-02-24 11:06 UTC [SEC Form SC TO-T/A filed](https://www.quantisnow.com/insight/sec-form-sc-to-ta-filed-426254)
- 2021-02-23 21:05 UTC [Leadership Update] [Ambrx Appoints Audit Executive Chris Nolet to Board of Directors](https://www.quantisnow.com/insight/ambrx-appoints-audit-executive-chris-nolet-to-board-of-directors-423696)
- 2021-02-22 12:00 UTC [Viela Bio to Report Fourth Quarter and Full Year 2020 Operating and Financial Results on March 1, 2021](https://www.quantisnow.com/insight/viela-bio-to-report-fourth-quarter-and-full-year-2020-417133)
- 2021-02-16 21:22 UTC [SEC Schedule 13G] [SEC Form SC 13G/A filed](https://www.quantisnow.com/insight/sec-form-sc-13ga-filed-402451)
- 2021-02-16 21:06 UTC [SEC Form 8-K filed](https://www.quantisnow.com/insight/sec-form-8-k-filed-401814)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/VIE
- Earnings history: https://www.quantisnow.com/earnings/VIE
- Dividend history: https://www.quantisnow.com/dividends/VIE
- Insider transactions: https://www.quantisnow.com/insiders/VIE
- Options chain: https://www.quantisnow.com/options/VIE
- SEC 8-K filings only: https://www.quantisnow.com/company/VIE/8-k
- RSS and alerts for VIE: https://www.quantisnow.com/docs/rss-feeds.md